🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,97 USD

Máx. histórico

89,55

118 días

Caída desde máximo

-22,98%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+1,25%

Cierre anterior

68,12

Rango de hoy

66,87 – 70,11

Volumen hoy

1.266.047

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,98%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 17 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
16/02/2018 24,40 24,98 23,84 23,93 -2,37% 4,67% 578.800
15/02/2018 24,75 24,85 23,55 24,51 +1,07% 5,25% 552.900
14/02/2018 23,13 24,46 23,12 24,25 +3,54% 5,79% 404.000
13/02/2018 22,87 23,98 22,72 23,42 +1,47% 5,51% 358.900
12/02/2018 23,24 24,24 22,67 23,08 +0,39% 6,77% 978.000
09/02/2018 23,50 23,89 21,97 22,99 -1,03% 8,17% 1.038.700
08/02/2018 24,83 25,02 23,00 23,23 -6,48% 8,14% 647.200
07/02/2018 25,05 25,14 24,53 24,84 +0,16% 2,44% 481.800
06/02/2018 23,55 25,09 23,15 24,80 +3,12% 8,22% 858.300
05/02/2018 24,24 25,40 23,98 24,05 -2,47% 5,86% 779.100
02/02/2018 24,91 25,69 24,12 24,66 -4,08% 6,30% 946.800
01/02/2018 26,29 26,50 25,42 25,71 -2,21% 4,11% 671.400
31/01/2018 26,92 27,37 26,11 26,29 -1,46% 4,68% 933.900
30/01/2018 26,49 27,62 25,35 26,68 -1,29% 8,58% 1.672.100
29/01/2018 25,19 28,75 24,66 27,03 +9,61% 16,24% 3.762.500
26/01/2018 23,65 25,19 23,03 24,66 +4,98% 9,13% 1.186.100
25/01/2018 23,25 23,84 23,04 23,49 +1,03% 3,45% 579.500
24/01/2018 23,70 23,70 22,60 23,25 -0,85% 4,64% 476.600
23/01/2018 22,82 23,60 22,73 23,45 +4,22% 3,81% 740.500
22/01/2018 22,21 22,58 21,63 22,50 +2,65% 4,28% 784.900
19/01/2018 21,11 22,35 20,80 21,92 +4,73% 7,34% 1.282.700
18/01/2018 21,94 22,05 20,73 20,93 -4,65% 6,02% 1.120.300
17/01/2018 21,76 21,98 20,99 21,95 +2,14% 4,55% 948.800
16/01/2018 23,49 23,64 21,40 21,49 -7,73% 9,54% 1.459.900
12/01/2018 21,94 23,71 21,44 23,29 +7,28% 10,35% 1.302.100
11/01/2018 20,50 21,82 20,21 21,71 +5,85% 7,85% 1.292.900
10/01/2018 20,50 21,00 20,02 20,51 -0,77% 4,78% 935.800
09/01/2018 20,38 20,80 20,25 20,67 +2,12% 2,70% 1.586.400
08/01/2018 18,18 20,65 18,16 20,24 +12,88% 13,70% 3.803.300
05/01/2018 18,09 18,21 17,76 17,93 -0,33% 2,49% 555.700